Laboratory Co. of America Holdings (NYSE:LH) Shares Bought by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC increased its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 12.3% during the 4th quarter, HoldingsChannel reports. The fund owned 6,834 shares of the medical research company’s stock after acquiring an additional 746 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Laboratory Co. of America were worth $1,567,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Graney & King LLC acquired a new position in shares of Laboratory Co. of America in the 4th quarter valued at approximately $26,000. Fortitude Family Office LLC grew its position in shares of Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Laboratory Co. of America by 309.8% in the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock worth $39,000 after buying an additional 127 shares during the last quarter. Human Investing LLC acquired a new stake in Laboratory Co. of America in the fourth quarter valued at $39,000. Finally, Heck Capital Advisors LLC bought a new position in Laboratory Co. of America during the 4th quarter valued at $44,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Stock Performance

Shares of NYSE LH opened at $228.54 on Friday. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59. The company has a market cap of $19.12 billion, a PE ratio of 25.91, a P/E/G ratio of 1.71 and a beta of 0.99. The stock has a 50 day simple moving average of $235.65 and a 200-day simple moving average of $234.90. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, equities research analysts forecast that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.26%. Laboratory Co. of America’s dividend payout ratio (DPR) is 32.65%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, April 18th. Piper Sandler upped their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. UBS Group decreased their target price on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Truist Financial dropped their price target on Laboratory Co. of America from $285.00 to $274.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Finally, Jefferies Financial Group lifted their price objective on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $268.77.

Insider Transactions at Laboratory Co. of America

In other news, CEO Adam H. Schechter sold 6,121 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total value of $1,497,319.02. Following the sale, the chief executive officer now owns 86,445 shares of the company’s stock, valued at approximately $21,146,175.90. The trade was a 6.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Mark S. Schroeder sold 5,339 shares of the firm’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $249.23, for a total value of $1,330,638.97. Following the transaction, the chief operating officer now directly owns 4,960 shares of the company’s stock, valued at $1,236,180.80. This represents a 51.84 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 14,258 shares of company stock valued at $3,518,177. Company insiders own 0.84% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.